Literature DB >> 21575286

Gout.

Martin Underwood1.   

Abstract

INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of treatments to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 16 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, corticotropin (ACTH), non-steroidal anti-inflammatory drugs (NSAIDs), sulfinpyrazone, xanthine oxidase inhibitors, advice to lose weight, advice to reduce alcohol intake, and advice to reduce dietary intake of purines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575286      PMCID: PMC3275296     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  43 in total

Review 1.  Gout: on the brink of novel therapeutic options for an ancient disease.

Authors:  Jeffry D Bieber; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2004-08

2.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

Authors:  Robert A Terkeltaub; Daniel E Furst; Katherine Bennett; Karin A Kook; R S Crockett; Matthew W Davis
Journal:  Arthritis Rheum       Date:  2010-04

3.  A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis.

Authors:  Tien-Tsai Cheng; Han-Ming Lai; Chun-Kai Chiu; Ying-Chou Chem
Journal:  Clin Ther       Date:  2004-03       Impact factor: 3.393

Review 4.  Gout in primary care.

Authors: 
Journal:  Drug Ther Bull       Date:  2004-05

5.  Alcohol intake and risk of incident gout in men: a prospective study.

Authors:  Hyon K Choi; Karen Atkinson; Elizabeth W Karlson; Walter Willett; Gary Curhan
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

6.  Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

Authors:  Bernard R Rubin; Robert Burton; Sandra Navarra; Joseph Antigua; John Londoño; Keith G Pryhuber; Margaret Lund; Erluo Chen; Daryl K Najarian; Richard A Petruschke; Zafer E Ozturk; Gregory P Geba
Journal:  Arthritis Rheum       Date:  2004-02

7.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

8.  Allopurinol treatment and its effect on renal function in gout: a controlled study.

Authors:  T Gibson; V Rodgers; C Potter; H A Simmonds
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

9.  Flurbiprofen in the treatment of acute gout. A comparison with indomethacin.

Authors:  P L Lomen; L F Turner; K R Lamborn; M A Winblad; R L Sack; E L Brinn
Journal:  Am J Med       Date:  1986-03-24       Impact factor: 4.965

10.  Preliminary criteria for the classification of the acute arthritis of primary gout.

Authors:  S L Wallace; H Robinson; A T Masi; J L Decker; D J McCarty; T F Yü
Journal:  Arthritis Rheum       Date:  1977-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.